Skip to main content
SpringerLink
Log in

Management of Malignant Pleural Effusion

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Respiratory Medicine ((RM))

  • 353 Accesses

Abstract

Malignant pleural effusion (MPE) is a common complication of advanced malignancy associated with high morbidity, mortality, and cost of care. The incidence of MPE is expected to rise with increasing global cancer rates, and optimal management will remain a chief concern for all practitioners involved in the care of patients with cancer. The management of MPE has advanced considerably in recent years in light of several high-quality randomized controlled trials and patient-centered focused clinical practice guidelines. Both indwelling pleural catheters and chemical pleurodesis are effective at improving symptoms. MPE, however, is a heterogenous disease, and multidisciplinary discussions centering on palliation and patient preferences remain the foundation of management. This chapter will comprehensively review the best evidence for diagnostic techniques and management options within MPE and highlight areas of ongoing research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ingelfinger JR, Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378:740–51.

    Article  Google Scholar 

  2. Taghizadeh N, Fortin M, Tremblay A. US Hospitalizations for Malignant Pleural Effusions Data From the 2012 National Inpatient Sample. Chest. 2017;151:845–54.

    Article  PubMed  Google Scholar 

  3. Antony V, Loddenkemper R, Astoui P, Boutin C, Goldstraw P. American thoracic society management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162:1987–2001.

    Article  Google Scholar 

  4. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside Number 1 in the Series “Pleural Diseases” Edited by Najib Rahman and Ioannis Psallidas. Eur Respir Rev. 2016;25:189–98.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Asciak R, Hallifax RJ, Mercer RM, Hassan M, Wigston C, Wrightson JM, Psallidas I, Rahman NM. The hospital and patient burden of indwelling pleural catheters: a retrospective case series of 210 indwelling pleural catheter insertions. Respiration. 2019;97:70–7.

    Article  PubMed  Google Scholar 

  6. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–9.

    Article  CAS  PubMed  Google Scholar 

  7. Chernow B, Sahn SA. Carcinomatous involvement of the pleura. An analysis of 96 patients. Am J Med. 1977;63:695–702.

    Article  CAS  PubMed  Google Scholar 

  8. Light R. Pleural diseases. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

    Google Scholar 

  9. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:ii32.

    Article  PubMed  Google Scholar 

  10. Merlo A, Strassle P, Gaber C, Mody GN. Time to malignant pleural effusion by cancer type and stage at presentation - an analysis of the surveillance, epidemiology and end results (SEER) Medicare database. J Am Coll Surg. 2020;231:S295.

    Article  Google Scholar 

  11. Feller-Kopman DJ, Reddy CB, Decamp MM, et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839–49.

    Article  PubMed  Google Scholar 

  12. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20:654–9.

    Article  PubMed  Google Scholar 

  13. Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018;52:1800349.

    Article  PubMed  Google Scholar 

  14. Anevlavis S, Kouliatsis G, Sotiriou I, Koukourakis MI, Archontogeorgis K, Karpathiou G, Giatromanolaki A, Froudarakis ME. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration. 2014;87:311–6.

    Article  PubMed  Google Scholar 

  15. Zamboni MM, da Silva CT, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:29. https://doi.org/10.1186/s12890-015-0025-z.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rusch VW, Chansky K, Kindler HL, et al. The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol. 2016;11:2112–9.

    Article  PubMed  Google Scholar 

  17. Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. Cham: Springer; 2017.

    Book  Google Scholar 

  18. Jacobs B, Sheikh G, Youness HA, Keddissi JI, Abdo T. Diagnosis and management of malignant pleural effusion: a decade in review. Diagnostics (Basel). 2022;12:1016. https://doi.org/10.3390/diagnostics12041016.

    Article  PubMed  Google Scholar 

  19. Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098–104.

    Article  PubMed  Google Scholar 

  20. Psallidas I, Kannelakis N, Yousuf A, Corcoran J, Hallifax R, Wrightson J, Mercer R, Talwar A, Rahman N. Lent score validation on patients with malignant pleural effusion. Eur Respir J. 2016;48:PA3385.

    Google Scholar 

  21. Psallidas I, Kanellakis NI, Gerry S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19:930–9.

    Article  PubMed  Google Scholar 

  22. Brims FJH, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. J Thorac Oncol. 2016;11:573–82.

    Article  PubMed  Google Scholar 

  23. Estenne M, Yernault JC, de Troyer A. Mechanism of relief of dyspnea after thoracocentesis in patients with large pleural effusions. Am J Med. 1983;74:813–9.

    Article  CAS  PubMed  Google Scholar 

  24. Thomas R, Jenkins S, Eastwood PR, Gary Lee YC, Singh B. Physiology of breathlessness associated with pleural effusions. Curr Opin Pulm Med. 2015;21:338.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Marel M, Stastny B, Melinova L, Svandova E, Light RW. Diagnosis of pleural effusions: experience with clinical studies, 1986 to 1990. Chest. 1995;107:1598–603.

    Article  CAS  PubMed  Google Scholar 

  26. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. Chest. 2003;124:978–83.

    Article  PubMed  Google Scholar 

  27. Maher GG, Berger HW. Massive pleural effusion: malignant and nonmalignant causes in 46 patients. Am Rev Respir Dis. 1972;105:458–60.

    CAS  PubMed  Google Scholar 

  28. Meyer PC. Metastatic carcinoma of the pleura. Thorax. 1966;21:437–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J. 1997;10:1701–2.

    Article  CAS  PubMed  Google Scholar 

  30. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.

    Article  PubMed  Google Scholar 

  31. Havelock T, Teoh R, Laws D, Gleeson F. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65:i61–76.

    Article  Google Scholar 

  32. Bugalho A, Ferreira D, Dias SS, Schuhmann M, Branco JC, Marques Gomes MJ, Eberhardt R. The diagnostic value of transthoracic ultrasonographic features in predicting malignancy in undiagnosed pleural effusions: a prospective observational study. Respiration. 2014;87:270–8.

    Article  PubMed  Google Scholar 

  33. Kaul V, Mccracken DJ, Rahman NM, Epelbaum O. FOCUSED REVIEW contemporary approach to the diagnosis of malignant pleural effusion. atsjournals.org. Ann Am Thorac Soc. 2019;16:1099–106.

    Article  PubMed  Google Scholar 

  34. Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis. 1989;139:663–7.

    Article  CAS  PubMed  Google Scholar 

  35. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest. 2000;117:87–95.

    Article  CAS  PubMed  Google Scholar 

  36. Porcel JM, Hernández P, Martínez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147:502–12.

    Article  PubMed  Google Scholar 

  37. Fjaellegaard K, Koefod Petersen J, Reuter S, Malene Fischer B, Gerke O, Porcel JM, Frost Clementsen P, Laursen CB, Bhatnagar R, Bodtger U. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. Lung Cancer. 2021;162:106–18.

    Article  PubMed  Google Scholar 

  38. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000;117:79–86.

    Article  CAS  PubMed  Google Scholar 

  39. Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med. 1988;108:345–9.

    Article  CAS  PubMed  Google Scholar 

  40. Rahman NM, Mishra EK, Davies HE, Davies RJO, Lee YCG. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med. 2008;178:483–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50:161–5.

    Article  PubMed  Google Scholar 

  42. Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018;52:1801254.

    Article  PubMed  Google Scholar 

  43. Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994;7:665–8.

    CAS  PubMed  Google Scholar 

  44. Naylor B, Schmidt RW. The case for exfoliative cytology of serous effusions. Lancet. 1964;1:711–2.

    Article  CAS  PubMed  Google Scholar 

  45. Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, Kini S, Kvale P. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010;137:68–73.

    Article  PubMed  Google Scholar 

  46. Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases. Cancer Cytopathol. 2014;122:657–65.

    Article  PubMed  Google Scholar 

  47. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R, Ji Q. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66:1065–9.

    Article  PubMed  Google Scholar 

  48. Light RW. Tumor markers in undiagnosed pleural effusions. Chest. 2004;126:1721–2.

    Article  PubMed  Google Scholar 

  49. Tang Y, Wang Z, Li Z, Kim J, Deng Y, Li Y, Heath JR, Wei W, Lu S, Shi Q. High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:2544–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Koegelenberg CFN, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EMA, Diacon AH. The utility of ultrasound-guided thoracentesis and pleural biopsy in undiagnosed pleural exudates. Thorax. 2015;70:995–7.

    Article  PubMed  Google Scholar 

  51. Qureshi NR, Rahman NM, Gleeson F. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64:139–43.

    Article  CAS  PubMed  Google Scholar 

  52. Maskell NA, Gleeson F, Davies RJO. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361:1326–30.

    Article  CAS  PubMed  Google Scholar 

  53. Metintas M, Yildirim H, Kaya T, Ak G, Dundar E, Ozkan R, Metintas S. CT scan-guided Abrams’ needle pleural biopsy versus ultrasound-assisted cutting needle pleural biopsy for diagnosis in patients with pleural effusion: a randomized, controlled trial. Respiration. 2016;91:156–63.

    Article  CAS  PubMed  Google Scholar 

  54. Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65:54–60.

    Article  Google Scholar 

  55. Rozman A, Camlek L, Marc Malovrh M, Kern I, Schönfeld N. Feasibility and safety of parietal pleural cryobiopsy during semi-rigid thoracoscopy. Clin Respir J. 2016;10:574–8.

    Article  PubMed  Google Scholar 

  56. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients part 1: diagnosis. Cancer. 1993;72:389–93.

    Article  CAS  PubMed  Google Scholar 

  57. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010;137:1362–8.

    Article  PubMed  Google Scholar 

  58. Murthy V, Bessich JL. Medical thoracoscopy and its evolving role in the diagnosis and treatment of pleural disease. J Thorac Dis. 2017;9:S1011–21.

    Article  PubMed  PubMed Central  Google Scholar 

  59. McDonald CM, Pierre C, de Perrot M, Darling G, Cypel M, Pierre A, Waddell T, Keshavjee S, Yasufuku K, Czarnecka-Kujawa K. Efficacy and cost of awake thoracoscopy and video-assisted thoracoscopic surgery in the undiagnosed pleural effusion. Ann Thorac Surg. 2018;106:361–7.

    Article  PubMed  Google Scholar 

  60. Roh J, Ahn HY, Kim I, Son JH, Seol HY, Kim MH, Lee MK, Eom JS, Lei G. Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients: a multicenter retrospective study. Medicine. 2021;100:E25748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest. 2013;143:532–8.

    Article  PubMed  Google Scholar 

  62. Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions. Chest. 2018;153:438.

    Article  PubMed  Google Scholar 

  63. Grosu HB, Molina S, Casal R, et al. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology. 2019;24:76.

    Article  PubMed  Google Scholar 

  64. Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016;2016:CD010529. https://doi.org/10.1002/14651858.CD010529.pub2.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Diacon AH, Wyser C, Bolliger CT, Tamm M, Pless M, Perruchoud AP, Solèr M. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med. 2000;162:1445–9.

    Article  CAS  PubMed  Google Scholar 

  66. Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020;2016:CD010529. https://doi.org/10.1002/14651858.CD010529.pub3.

    Article  Google Scholar 

  67. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38.

    Article  PubMed  Google Scholar 

  68. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909.

    Article  PubMed  Google Scholar 

  69. Mummadi S, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. F1000Research. 2014;3:254. https://doi.org/10.12688/f1000research.5538.2.

    Article  PubMed  Google Scholar 

  70. Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial. JAMA. 2020;323:60–9.

    Article  PubMed  Google Scholar 

  71. Psallidas I, Hassan M, Yousuf A, et al. Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial. Lancet Respir Med. 2022;10:139–48.

    Article  CAS  PubMed  Google Scholar 

  72. Wilshire CL, Chang SC, Gilbert CR, et al. Temporal trends in tunneled pleural catheter utilization in patients with malignancy: a multicenter review. Chest. 2021;159:2483–7.

    Article  PubMed  Google Scholar 

  73. Ost DE, Jimenez CA, Lei X, et al. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest. 2014;145:1347–56.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Sabur NF, Chee A, Stather DR, MacEachern P, Amjadi K, Hergott CA, Dumoulin E, Gonzalez A, Tremblay A. The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration. 2013;85:36–42.

    Article  PubMed  Google Scholar 

  75. Gilbert CR, Lee HJ, Skalski JH, et al. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study. Chest. 2015;148:752–8.

    Article  PubMed  PubMed Central  Google Scholar 

  76. van Meter MEM, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26:70–6.

    Article  PubMed  Google Scholar 

  77. Sundaralingam A, Bedawi EO, Harriss EK, Munavvar M, Rahman NM. The frequency, risk factors, and management of complications from pleural procedures. Chest. 2022;161:1407–25.

    Article  PubMed  Google Scholar 

  78. Miller RJ, Chrissian AA, Lee YCG, et al. AABIP evidence-informed guidelines and expert panel report for the management of indwelling pleural catheters. J Bronchol Interv Pulmonol. 2020;27:229–45.

    Article  Google Scholar 

  79. Gilbert CR, Wahidi MM, Light RW, et al. Management of indwelling tunneled pleural catheters: a modified Delphi consensus statement. Chest. 2020;158:2221–8.

    Article  PubMed  Google Scholar 

  80. Frost N, Brünger M, Ruwwe-Glösenkamp C, Raspe M, Tessmer A, Temmesfeld-Wollbrück B, Schürmann D, Suttorp N, Witzenrath M. Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre’s ten years of experience. BMC Pulm Med. 2019;19:1–10.

    Article  Google Scholar 

  81. Fysh ETH, Wrightson JM, Lee YCG, Rahman NM. Fractured indwelling pleural catheters. Chest. 2012;141:1090–4.

    Article  PubMed  Google Scholar 

  82. Matus I, Colt H. Pleural catheter fracture during IPC removal: an under-reported Complication. J Bronchol Interv Pulmonol. 2021;28:E1–3.

    Article  Google Scholar 

  83. Wahidi MM, Reddy C, Yarmus L, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med. 2017;195:1050–7.

    Article  PubMed  Google Scholar 

  84. Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6:671–80.

    Article  PubMed  Google Scholar 

  85. Shafiq M, Frick KD, Lee H, Yarmus L, Feller-Kopman DJ. Management of malignant pleural effusion: a cost-utility analysis. J Bronchol Interv Pulmonol. 2015;22:215–25.

    Article  Google Scholar 

  86. Gilbert CR, Akulian JA, Gorden JA. The impact of the ASAP trial: maybe we shouldn’t act so quickly. Am J Respir Crit Care Med. 2018;197:142–3.

    Article  PubMed  Google Scholar 

  87. Putnam JB, Light RW, Michael Rodriguez R, Ponn R, Olak J, Pollak JS, Lee RB, Keith D, Graeber G, Kovitz KL. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86:1992–9.

    Article  PubMed  Google Scholar 

  88. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307:2383–9.

    Article  CAS  PubMed  Google Scholar 

  89. Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA. 2017;318:1903–12.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378:1313–22.

    Article  CAS  PubMed  Google Scholar 

  91. ClinicalTrials.gov. Duke University randomized controlled trial of talc instillation in addition to daily drainage through a tunneled pleural catheter to improve rates of outpatient pleurodesis in patients with malignant pleural effusion. n.d.. https://clinicaltrials.gov/ct2/show/NCT04792970. Accessed 13 Aug 2022.

  92. Fitzgerald DB, Muruganandan S, Stanley C, Badiei A, Murray K, Read CA, Lee YCG. EPIToME (early pleurodesis via IPC with talc for malignant effusion): evaluation of a new management algorithm. Eur Respir J. 2019;54:OA493.

    Google Scholar 

  93. Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–27.

    Article  PubMed  Google Scholar 

  94. Martin GA, Tsim S, Kidd AC, Foster JE, McLoone P, Chalmers A, Blyth KG. Pre-EDIT: a randomized feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis in malignant pleural effusion. Chest. 2019;156:1204–13.

    Article  PubMed  Google Scholar 

  95. Chopra A, Judson MA, Doelken P, Maldonado F, Rahman NM, Huggins JT. The relationship of pleural manometry with postthoracentesis chest radiographic findings in malignant pleural effusion. Chest. 2020;157:421–6.

    Article  PubMed  Google Scholar 

  96. Salamonsen MR, Lo AKC, Ng ACT, Bashirzadeh F, Wang WYS, Fielding DIK. Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. Chest. 2014;146:1286–93.

    Article  PubMed  Google Scholar 

  97. Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. Chest. 2006;129:1556–60.

    Article  PubMed  Google Scholar 

  98. Psallidas I, Yousuf A, Talwar A, Hallifax RJ, Mishra EK, Corcoran JP, Ali N, Rahman NM. Assessment of patient-reported outcome measures in pleural interventions. BMJ Open Respir Res. 2017;4:e000171. https://doi.org/10.1136/BMJRESP-2016-000171.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Mishra EK, Clive AO, Wills GH, et al. Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med. 2018;197:502–8.

    Article  CAS  PubMed  Google Scholar 

  100. Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8:e1554969. https://doi.org/10.1080/2162402X.2018.1554969.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Aggarwal C, Haas AR, Metzger S, et al. Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion. Mol Ther. 2018;26:1198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Fitzgerald DB, Sidhu C, Budgeon C, et al. Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion. Trials. 2022;23:530.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Rivera MP. Management of malignant pleural effusions: round and round we go. Ann Am Thorac Soc. 2019;16:59–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, United States

    Benjamin DeMarco

  2. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA

    Christina R. MacRosty

Authors
  1. Benjamin DeMarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina R. MacRosty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina R. MacRosty .

Editor information

Editors and Affiliations

  1. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA

    Christina R. MacRosty

  2. Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA

    M. Patricia Rivera

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

DeMarco, B., MacRosty, C.R. (2023). Management of Malignant Pleural Effusion. In: MacRosty, C.R., Rivera, M.P. (eds) Lung Cancer. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-031-38412-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38412-7_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-38411-0

  • Online ISBN: 978-3-031-38412-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation